This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cellectis Grants Harvard Bioscience A License To CytoPulse Electroporation Instruments

PARIS and HOLLISTON, Mass., Dec. 2, 2010 (GLOBE NEWSWIRE) -- Cellectis (Alternext:ALCLS), the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, have announced today that they have signed a license agreement that grants Harvard Apparatus the worldwide exclusive right to manufacture and sell, for research use, the full line of electroporation-based instruments acquired by Cellectis from CytoPulse in September of 2010. Cellectis retains all rights to the use of these products for its own research and development programs as well as in clinical trials and prophylactic or therapeutic procedures, for both humans and animals.

In the agreement, Cellectis will receive a payment of $1.3M from Harvard Apparatus. Cellectis will retain some annual licensing fees owed by existing and new customers. The CytoPulse instruments involved include DermaVax, OncoVet, Hybrimune, Cyto-LVT-S and Cyto-LVT-P.

" We are delighted to work with Harvard Apparatus on the distribution of this very efficient technology," declared Dirk Pollet, Chief Business Officer for Cellectis. " This deal provides Harvard Apparatus with an excellent new product line, while generating a robust revenue stream for Cellectis. In addition, it allows the technology to be made available to the research community to explore its potential."

Chane Graziano, CEO of Harvard Bioscience, commented, "This license significantly expands the cell biology research product line offered by Harvard Apparatus under the Warner Instruments and BTX brands. The technology is quite unique and patent protected and will provide our research customers with new tools to perform their electroporation and electrofusion experiments."

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -- meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs